Govinda J. Weerakkody

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine · 2007 · 6.7K citations · Full text

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

A. Michael Lincoff, Stephen J. Nicholls, Jeffrey Riesmeyer et al. · New England Journal of Medicine · 2017 · 768 citations · Full text

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y ₁₂ Antagonist, With Clopidogrel in Percutaneous Coronary Intervention

Stephen D. Wiviott, Elliott M. Antman, Kenneth J. Winters et al. · Circulation · 2005 · 379 citations · Full text

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)

Stephen D. Wiviott, Elliott M. Antman, C. Michael Gibson et al. · American Heart Journal · 2006 · 327 citations

Thrombosis, Cardiovascular Disease, Blood Platelet +12